普蕊斯 (301257)
SMO ClinPlus CO., LTD.
K-Line Chart
No K-line data available
Company NamePruis (Shanghai) Pharmaceutical Technology Development Co., Ltd.
Listing Date2022-05-17
Issue Price46.8RMB
Registered Capital7900.47710k RMB
Legal RepresentativeLai Chunbao
Registered AddressRoom 108, Building 1, No. 105 Sinan Road, Huangpu District, Shanghai
IndustryMedical Services
Main BusinessProviding SMO services for clinical research and development to domestic and international pharmaceutical companies, medical device companies, and certain health-related products.
Company ProfilePruis (Shanghai) Pharmaceutical Technology Development Co., Ltd. provides SMO services for the clinical research and development of domestic and international pharmaceutical companies, medical device companies, and certain health-related products. Based on accumulated experience in executing clinical trial projects from past operations, the company establishes practical and feasible clinical trial project execution plans tailored to the characteristics of different trials. It offers clients a full range of services including preliminary planning, site initiation, on-site execution, and end-to-end project management, delivering one-stop outsourced management for clinical trials, thereby more efficiently and rapidly advancing the implementation and execution of sponsor's clinical trials.
After years of rapid development, the company boasts over 2,100 professional staff, serves more than 600 clinical trial sites, covers over 140 cities nationwide, and has accumulated experience in over 1,300 international multi-center and domestic Class I new drug clinical projects. It has facilitated the market launch of over 50 drug or medical device products domestically and internationally, establishing a comprehensive standardized management and quality control system.
Stock Details
1. Key Indicators
- Total Shares(W): 7900.48
- Circulating A-Shares(W): 7531.89
- Earnings Per Share(RMB): 1.1100
- Net Assets Per Share(RMB): 15.8550
- Operating Revenue(W RMB): 60901.16
- Total Profit(W RMB): 9859.53
- Net Profit Attributable to Parent(W RMB): 8738.15
- Net Profit Growth Rate(%): 20.92
- Weighted Return on Equity(%): 7.2000
- Operating Cash Flow Per Share(RMB): 0.1930
- Undistributed Profit Per Share(RMB): 6.1629
- Capital Reserve Per Share(RMB): 8.1921
2. Main Business
The main business covers:
- Big data-driven clinical research services
- Services including pre-preparation planning, trial site initiation, on-site execution, and full project process management
3. Company Basic Information
- Company Name: Smo Clinplus Co., Ltd.
- Listing Date: 2022-05-17
- Industry: Research and Experimental Development
- Address: 23F, World Trade Mansion, No. 500 Guangdong Road, Huangpu District, Shanghai
- Website: www.smo-clinplus.com
- Company Profile：On May 20, 2016, the Shanghai Administration for Industry and Commerce issued the "Notice of Pre-approval of Enterprise Name Change" with the number "Hu Gong Shang Zhu Ming Yu He Zi No. 01201605200446", approving
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shihezi Xitai Equity Investment Partnership Enterprise (Limited Partnership) | General Legal Person | 1477.35 | 19.61 |
| 2 | Shihezi Ruixin Equity Investment Partnership Enterprise (Limited Partnership) | General Legal Person | 639.76 | 8.49 |
| 3 | Shihezi Ruizesheng Equity Investment Co., Ltd. | General Legal Person | 585.00 | 7.77 |
| 4 | Shanghai Guanyou Investment Development Co., Ltd. - Guanyou Zhaotai (Jiaxing) Venture Capital Partnership Enterprise (Limited Partnership) | General Legal Person | 547.40 | 7.27 |
| 5 | Noah Pioneer Mixed Securities Investment Fund Class A | Fund | 329.19 | 4.37 |
| 6 | Tianhong Medical Health Mixed Securities Investment Fund Class A | Fund | 96.10 | 1.28 |
| 7 | China Resources Trust Co., Ltd. - China Resources Trust · Shenzhi Asset Xingzhi Collective Fund Trust Plan | General Legal Person | 90.47 | 1.20 |
| 8 | Nanhua Fenghui Mixed Securities Investment Fund Class A | Fund | 20.34 | 0.27 |
| 9 | Chuangjin Hexin Da Jiankang Mixed Securities Investment Fund Class A | Fund | 12.10 | 0.16 |
| 10 | Xingyin Fengyun Wenyi Return Mixed Securities Investment Fund Class A | Fund | 9.49 | 0.13 |
5. Concept Sectors
- Immunotherapy
- CXO Concept
- Hepatitis Concept
- Innovative Drugs
- Weight Loss Drugs
- DeepSeek
- Margin Trading
- High-Performance Stocks
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information